Affordable Access

deepdyve-link
Publisher Website

Modulation of immune responses in lentiviral vector-mediated gene transfer.

Authors
  • Annoni, Andrea1
  • Gregori, Silvia2
  • Naldini, Luigi3
  • Cantore, Alessio4
  • 1 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: [email protected] , (Italy)
  • 2 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy. , (Italy)
  • 3 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita Salute San Raffaele University, Milan, Italy. , (Italy)
  • 4 San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita Salute San Raffaele University, Milan, Italy. Electronic address: [email protected] , (Italy)
Type
Published Article
Journal
Cellular Immunology
Publisher
Elsevier
Publication Date
Aug 01, 2019
Volume
342
Pages
103802–103802
Identifiers
DOI: 10.1016/j.cellimm.2018.04.012
PMID: 29735164
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Lentiviral vectors (LV) are widely used vehicles for gene transfer and therapy in pre-clinical animal models and clinical trials with promising safety and efficacy results. However, host immune responses against vector- and/or transgene-derived antigens remain a major obstacle to the success and broad applicability of gene therapy. Here we review the innate and adaptive immunological barriers to successful gene therapy, both in the context of ex vivo and in vivo LV gene therapy, mostly concerning systemic LV delivery and discuss possible means to overcome them, including vector design and production and immune modulatory strategies. Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times